DE60111068D1 - Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit - Google Patents

Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit

Info

Publication number
DE60111068D1
DE60111068D1 DE60111068T DE60111068T DE60111068D1 DE 60111068 D1 DE60111068 D1 DE 60111068D1 DE 60111068 T DE60111068 T DE 60111068T DE 60111068 T DE60111068 T DE 60111068T DE 60111068 D1 DE60111068 D1 DE 60111068D1
Authority
DE
Germany
Prior art keywords
present
directed
patient
flowable composition
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60111068T
Other languages
English (en)
Other versions
DE60111068T3 (de
DE60111068T2 (de
Inventor
L Dunn
S Garrett
Harish Ravivarapu
L Chandrashekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolmar Therapeutics Inc
Original Assignee
Atrix Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27099398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60111068(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atrix Laboratories Inc filed Critical Atrix Laboratories Inc
Publication of DE60111068D1 publication Critical patent/DE60111068D1/de
Application granted granted Critical
Publication of DE60111068T2 publication Critical patent/DE60111068T2/de
Publication of DE60111068T3 publication Critical patent/DE60111068T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3205Separate rigid or semi-rigid containers joined to each other at their external surfaces
DE60111068.4T 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit Expired - Lifetime DE60111068T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66617400A 2000-09-21 2000-09-21
US666174 2000-09-21
US711758 2000-11-13
US09/711,758 US6565874B1 (en) 1998-10-28 2000-11-13 Polymeric delivery formulations of leuprolide with improved efficacy
EP01973341.9A EP1322286B3 (de) 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
PCT/US2001/029612 WO2002030393A2 (en) 2000-09-21 2001-09-21 Polymeric delivery formulations of leuprolide with improved efficacy

Publications (3)

Publication Number Publication Date
DE60111068D1 true DE60111068D1 (de) 2005-06-30
DE60111068T2 DE60111068T2 (de) 2006-01-26
DE60111068T3 DE60111068T3 (de) 2018-01-04

Family

ID=27099398

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60111068.4T Expired - Lifetime DE60111068T3 (de) 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
DE60141421T Expired - Lifetime DE60141421D1 (de) 2000-09-21 2001-09-21 Polymere Verabreichungsform von Leuprolid mit verbesserter Wirksamkeit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60141421T Expired - Lifetime DE60141421D1 (de) 2000-09-21 2001-09-21 Polymere Verabreichungsform von Leuprolid mit verbesserter Wirksamkeit

Country Status (27)

Country Link
US (8) US6565874B1 (de)
EP (3) EP2158900B1 (de)
JP (4) JP2004510807A (de)
KR (1) KR100831113B1 (de)
CN (2) CN101669900B (de)
AT (2) ATE296088T3 (de)
AU (4) AU2001292931B2 (de)
BR (1) BRPI0114069B8 (de)
CA (1) CA2436275C (de)
CY (2) CY1110653T1 (de)
CZ (1) CZ303134B6 (de)
DE (2) DE60111068T3 (de)
DK (3) DK2158900T3 (de)
ES (3) ES2341777T7 (de)
HK (2) HK1139596A1 (de)
HU (1) HU228386B1 (de)
IL (2) IL155006A0 (de)
IS (1) IS6794A (de)
MX (1) MXPA03002552A (de)
NZ (1) NZ525210A (de)
PL (1) PL226346B1 (de)
PT (3) PT1322286E (de)
RU (1) RU2271826C2 (de)
SI (1) SI1322286T1 (de)
SK (1) SK287528B6 (de)
WO (1) WO2002030393A2 (de)
ZA (1) ZA200302944B (de)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
ATE322513T1 (de) * 2000-08-07 2006-04-15 Wako Pure Chem Ind Ltd Milchsäurepolymer und verfahren zu dessen herstellung
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
JP2005534647A (ja) 2002-06-07 2005-11-17 ダイアックス、コープ 失血の予防及び軽減
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー,インコーポレイテッド. 細胞スケジュール依存性抗癌剤のための処方
PL1603532T3 (pl) * 2003-03-14 2009-02-27 Debio Rech Pharmaceutique S A System dostarczania podskórnego, sposób jego wytwarzania oraz jego zastosowanie do leczenia zaburzeń z deficytem cholinergicznym
US20040248804A1 (en) * 2003-05-01 2004-12-09 Khurshid Iqbal Nasal administration of the LH-RH analog Leuprolide
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
WO2005070444A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
EP1703916A2 (de) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Verfahren zur behandlung eines akuten myokardinfarkts mit einem mit dem calicitonin-gen in verbindung stehenden peptid sowie dieses enthaltende zusammensetzungen
EP1703895A2 (de) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Zusammensetzung zur cgrp anwendung mit kontrollierter freigabe zur behandlung von kardiovaskulären oder nieren indikationen
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
EP1729829A1 (de) * 2004-03-02 2006-12-13 Nanotherapeutics, Inc. Zusammensetzungen zur knochen wiederherstellung und verfahren zu deren herstellung und deren verwendung
TW200533385A (en) * 2004-03-03 2005-10-16 Commw Scient Ind Res Org Biocompatible polymer compositions for dual or multi staged curing
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP2216026B1 (de) * 2004-07-12 2016-04-20 Allergan, Inc. Ophthalmologische Zusammensetzungen und deren Verwendung zur Behandlung von Augenkrankheiten
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2006065951A2 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US20060189958A1 (en) * 2005-02-21 2006-08-24 Talton James D Inverted cannula for use in reconstituting dry material in syringes
KR101072239B1 (ko) * 2005-06-07 2011-10-12 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 촉매 캐리어
WO2007011340A1 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US7563223B2 (en) 2005-08-08 2009-07-21 Cytye Corporation Tumescent skin spacing method
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
WO2007082726A2 (de) * 2006-01-17 2007-07-26 Medigene Ag Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
JP4682251B2 (ja) * 2006-02-02 2011-05-11 トリメリス,インコーポレーテッド 改善された生物学的特性を有するhiv融合阻害剤ペプチド
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
US8013061B2 (en) * 2006-03-08 2011-09-06 The University Of North Carolina At Chapel Hill Polyester based degradable materials and implantable biomedical articles formed therefrom
CN101511380B (zh) 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
US8076448B2 (en) * 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
AR063620A1 (es) * 2006-11-09 2009-02-04 Alcon Res Ltd Implante punctal que contiene una matriz polimerica insoluble en agua
TWI409081B (zh) * 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
BRPI0720582B1 (pt) * 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
DK2115029T3 (en) * 2007-02-15 2015-10-05 Tolmar Therapeutics Inc LAVSPRÆNGNING poly (lactide / glycolide) and methods to produce polymers
WO2008124013A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
US10010612B2 (en) * 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
RU2010113998A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида rfmwmr в качестве терапевтического средства
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
US20090112193A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices that utilize photolyzable nitric oxide donors
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8828354B2 (en) * 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9125917B2 (en) 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US20090264478A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Sulfasalazine formulations in a biodegradable polymer carrier
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
AU2009255675B2 (en) * 2008-06-03 2014-10-09 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
ES2569556T3 (es) 2008-06-03 2016-05-11 Indivior Uk Limited Complejo de inclusión de hidrogel deshidratado de un agente bioactivo con sistema fluido de administración de medicamento
ES2535330T3 (es) * 2008-06-03 2015-05-08 Tolmar Therapeutics, Inc. Composición fluida que comprende composiciones poliméricas y oligoméricas biocompatibles
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
CN101653422B (zh) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
US8469779B1 (en) 2009-01-02 2013-06-25 Lifecell Corporation Method for debristling animal skin
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8758791B2 (en) * 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
EP2394663B1 (de) 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Zusammensetzungen für injizierbare, in-situ biologisch abbaubare Implantate
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
DK2394664T3 (en) 2010-05-31 2016-09-12 Laboratorios Farmacéuticos Rovi S A Antipsychotic injectable depot composition
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EP2585092A1 (de) * 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmazeutische zusammensetzung mit goserelin für ein in-situ-implantat
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
NO2658525T3 (de) 2010-12-29 2018-01-27
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8637067B1 (en) 2011-03-10 2014-01-28 Lifecell Corporation Elastic tissue matrix derived hydrogel
CA2832838C (en) 2011-04-14 2019-08-13 Lifecell Corporation Regenerative tissue matrix flakes
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9089523B2 (en) 2011-07-28 2015-07-28 Lifecell Corporation Natural tissue scaffolds as tissue fillers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
AU2012355463C1 (en) 2011-12-20 2016-09-22 Lifecell Corporation Sheet tissue products
ES2860464T3 (es) 2011-12-20 2021-10-05 Lifecell Corp Productos de tejido fluidizable
CA2861048C (en) 2012-01-24 2021-01-12 Lifecell Corporation Elongated tissue matrices
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
WO2013163186A1 (en) 2012-04-24 2013-10-31 Lifecell Corporation Flowable tissue matrices
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
WO2014011402A1 (en) 2012-07-13 2014-01-16 Lifecell Corporation Methods for improved treatment of adipose tissue
BR112015006393A2 (pt) 2012-09-26 2017-07-04 Lifecell Corp método para produzir um produto de tecido, produto de tecido produzido por um processo, e método de tratamento
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US9592254B2 (en) 2013-02-06 2017-03-14 Lifecell Corporation Methods for localized modification of tissue products
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3122782A4 (de) 2014-03-27 2017-09-13 Dyax Corp. Zusammensetzungen und verfahren zur behandlung von diabetischem makulaödem
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
CA2994704A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
WO2017084973A1 (en) * 2015-11-16 2017-05-26 Evonik Röhm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
US10792394B2 (en) 2016-06-03 2020-10-06 Lifecell Corporation Methods for localized modification of tissue products
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2018102700A1 (en) * 2016-12-01 2018-06-07 Pinscreen, Inc. Photorealistic facial texture inference using deep neural networks
AU2017382173A1 (en) 2016-12-22 2019-06-06 Lifecell Corporation Devices and methods for tissue cryomilling
HRP20220438T1 (hr) * 2017-01-31 2022-06-10 Veru Inc. Pripravci i postupci za dugotrajno oslobađanje antagonista ganadotropin oslobađajućeg hormona (gnrh)
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR102412628B1 (ko) * 2017-08-28 2022-06-23 차의과학대학교 산학협력단 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법
EP3639856B1 (de) * 2017-09-27 2022-08-03 Novel Pharma Inc. Langwirkendes palmitinsäurekonjugiertes gnrh-derivat und dieses enthaltende pharmazeutische zusammensetzung
US10821205B2 (en) 2017-10-18 2020-11-03 Lifecell Corporation Adipose tissue products and methods of production
US11123375B2 (en) 2017-10-18 2021-09-21 Lifecell Corporation Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
CA3075106A1 (en) 2017-10-19 2019-04-25 Lifecell Corporation Flowable acellular tissue matrix products and methods of production
US11246994B2 (en) 2017-10-19 2022-02-15 Lifecell Corporation Methods for introduction of flowable acellular tissue matrix products into a hand
EP3727421A4 (de) * 2017-12-18 2021-07-28 Foresee Pharmaceuticals Co., Ltd. Pharmazeutische zusammensetzungen mit einer ausgewählten freisetzungsdauer
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
BR112020023983A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
US20220040201A1 (en) * 2018-09-25 2022-02-10 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
US20200330547A1 (en) * 2019-04-22 2020-10-22 Tolmar International Limited Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
WO2020243497A1 (en) 2019-05-30 2020-12-03 Lifecell Corporation Biologic breast implant
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
JP2023532107A (ja) 2020-06-30 2023-07-26 チョン クン ダン ファーマシューティカル コーポレーション Gnrh誘導体を含む注射用組成物
EP4221688A1 (de) 2020-09-30 2023-08-09 Tolmar International Limited Biologisch abbaubare polymer- und lösungsmittelzusammensetzungen sowie systeme zur verlängerten lagerung und abgabe von pharmazeutischen wirkstoffen
US11908233B2 (en) 2020-11-02 2024-02-20 Pinscreen, Inc. Normalization of facial images using deep neural networks
TW202235113A (zh) 2020-12-23 2022-09-16 愛爾蘭商托爾瑪國際有限公司 用於混合注射器閥組件之系統及方法
KR102386163B1 (ko) 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284417A (en) * 1963-11-13 1966-11-08 Union Carbide Corp Process for the preparation of lactone polyesters
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4040420A (en) * 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2988633B2 (ja) 1990-03-16 1999-12-13 三和生薬株式会社 発毛・育毛剤
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747637A (en) * 1995-09-07 1998-05-05 Mitsui Toatsu Chemicals, Inc. Bioabsorbable polymer and process for preparing the same
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
DK1238657T3 (da) * 1996-02-02 2005-01-17 Alza Corp Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system
US6130200A (en) * 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
JPH10279499A (ja) * 1997-04-04 1998-10-20 Takeda Chem Ind Ltd 子宮粘膜適用製剤
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US6555645B1 (en) 1999-09-10 2003-04-29 Mitsui Chemicals, Inc. Degradable polyurethane resin
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2005059003A1 (en) * 2003-12-15 2005-06-30 The Children's Hospital Of Philadelphia Novel polyesters

Also Published As

Publication number Publication date
US20100234305A1 (en) 2010-09-16
US8486455B2 (en) 2013-07-16
SI1322286T1 (en) 2005-10-31
US9254307B2 (en) 2016-02-09
HK1139596A1 (en) 2010-09-24
DE60141421D1 (de) 2010-04-08
PL226346B1 (pl) 2017-07-31
NZ525210A (en) 2004-10-29
ES2341777T7 (es) 2020-05-08
JP6087886B2 (ja) 2017-03-01
PT1586309E (pt) 2010-05-28
US20150150937A1 (en) 2015-06-04
WO2002030393A3 (en) 2002-06-27
CA2436275C (en) 2007-01-02
ATE458469T3 (de) 2010-03-15
JP2014240439A (ja) 2014-12-25
JP6061823B2 (ja) 2017-01-18
AU2010201645B2 (en) 2012-07-12
SK287528B6 (sk) 2011-01-04
KR100831113B1 (ko) 2008-05-20
CN1474685A (zh) 2004-02-11
BRPI0114069B1 (pt) 2016-08-23
IS6794A (is) 2003-04-23
AU9293101A (en) 2002-04-22
EP1322286A2 (de) 2003-07-02
DK1322286T3 (da) 2005-08-01
ES2241876T3 (es) 2005-11-01
PT2158900E (pt) 2013-03-11
EP1322286B1 (de) 2005-05-25
EP1586309A1 (de) 2005-10-19
IL155006A0 (en) 2003-10-31
US20160106805A1 (en) 2016-04-21
US6773714B2 (en) 2004-08-10
JP2013253101A (ja) 2013-12-19
JP2012012418A (ja) 2012-01-19
CY1110653T1 (el) 2015-06-10
DE60111068T3 (de) 2018-01-04
ZA200302944B (en) 2004-08-24
EP1322286B3 (de) 2017-08-16
US20040229912A1 (en) 2004-11-18
ES2404559T3 (es) 2013-05-28
SK5152003A3 (en) 2003-10-07
AU2010201645A1 (en) 2010-05-20
EP1586309B1 (de) 2010-02-24
HUP0302981A2 (hu) 2004-01-28
ES2341777T3 (es) 2010-06-28
CN101669900B (zh) 2013-07-24
HK1141459A1 (en) 2010-11-12
CN101669900A (zh) 2010-03-17
ES2241876T7 (es) 2018-02-16
CN100536922C (zh) 2009-09-09
CZ303134B6 (cs) 2012-04-25
DK1586309T3 (da) 2010-06-14
US20070104759A1 (en) 2007-05-10
BRPI0114069B8 (pt) 2021-05-25
DK1586309T6 (da) 2019-10-07
RU2271826C2 (ru) 2006-03-20
BR0114069A (pt) 2004-02-10
CZ20031124A3 (cs) 2003-12-17
HU228386B1 (hu) 2013-03-28
WO2002030393A2 (en) 2002-04-18
PT1322286E (pt) 2005-08-31
JP5969190B2 (ja) 2016-08-17
JP2004510807A (ja) 2004-04-08
IL155006A (en) 2007-06-03
EP1586309B3 (de) 2019-09-18
MXPA03002552A (es) 2005-09-08
HUP0302981A3 (en) 2006-07-28
CY1113920T1 (el) 2016-07-27
PL361671A1 (en) 2004-10-04
AU2001292931B2 (en) 2006-08-24
DE60111068T2 (de) 2006-01-26
AU2006241376B2 (en) 2010-02-04
CA2436275A1 (en) 2002-04-18
EP2158900A1 (de) 2010-03-03
US20100226954A1 (en) 2010-09-09
DK2158900T3 (da) 2013-02-18
ATE296088T3 (de) 2005-06-15
AU2006241376A1 (en) 2006-12-14
KR20030064401A (ko) 2003-07-31
US6565874B1 (en) 2003-05-20
US20030133964A1 (en) 2003-07-17
EP2158900B1 (de) 2013-01-23
DK1322286T6 (da) 2017-11-13

Similar Documents

Publication Publication Date Title
DE60111068D1 (de) Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
DE69925461D1 (de) Zielgerichtete abgabe von biologische-aktive medien
WO2004069335A3 (en) Magnetic implants to treat body tissue structures
PT637933E (pt) Metodo para tratamento de orgaos e tecidos
ATE209907T1 (de) Flüssige mittel zur wirkstoffabgabe
PT774964E (pt) Entrega local controlada de agentes quimioterapeuticos para tratamento de tumores solidos
WO2005025508A3 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
PT1315771E (pt) Material biologicamente activo
WO2004012676A3 (en) Drug-loaded biological material chemically treated with genipin
DE60229118D1 (de) Polynukleotide-bindende komplexe die sterolen und saponine enthalten
BRPI0117343B8 (pt) composição fluida para uso como um implante de liberação controlada, processo para formação da mesma, uso, kit e implante sólido
DeRoberts et al. Intense Pulsed Light Tattoo Removal in Conjunction with Imiquimod (Aldaraо): A Double-Blind, Randomized Controlled Study
ITBO990111A1 (it) Prodotto , metodo ed uso di poliacrilammide come veicolo per sostanzefarmacologiche .

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: QLT USA, INC. (N.D.GES.D. STAATES DELAWARE), FORT

8364 No opposition during term of opposition